Financings in Brief: Spine-Tech
This article was originally published in The Gray Sheet
Executive SummarySpine-Tech: Nets approximately $4.4 mil. in additional funds as underwriters Robertson, Stephens and Piper Jaffray exercise their over-allotment option in the firm's initial public offering. The underwriters sold 525,000 additional shares for $9 each, the firm says. With the over-allotment, total net proceeds from Minneapolis-based Spine-Tech's IPO are about $26 mil. A registration statement for the IPO was filed in May ("The Gray Sheet" May 29, p. 14); the offering was completed June 27...
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.